JAMA Psychiatry最新文献

{"title":"Blinding Integrity and Psychedelic Drug Trials.","authors":"Michael Elliott, Olga Chernoloz","doi":"10.1001/jamapsychiatry.2026.2293","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2293","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":18.0,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychotherapy for Impact of Killing During War","authors":"Shira Maguen, Rebecca Gloria, Amy Lehrner, Jean C. Beckham, Stephanie Y. Wells, Laura Pratchett, Jamil Davis, Deborah E. Barnes, Kristine Burkman","doi":"10.1001/jamapsychiatry.2026.2307","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2307","url":null,"abstract":"Importance Killing in war is associated with multiple adverse outcomes, including posttraumatic stress disorder (PTSD), moral injury (MI), and suicide. Impact of killing (IOK) is an individual psychotherapy developed to treat the mental health impact of killing in war. Objective To determine whether IOK improves veterans’ mental health symptoms and functioning at posttreatment and 6-month follow-up. Design, Setting, and Participants This multisite, superiority, randomized clinical trial was conducted from August 2018 to November 2023. Participants were veterans randomized to IOK or present-centered therapy (PCT). Diagnostic assessments were administered at screening and posttreatment by blinded evaluators. Self-report measures were collected at baseline, midtreatment, posttreatment, and 6-month follow-up at 3 Veterans Affairs health care systems in California, New York, and North Carolina via in-person and remote appointments. Participants were a sample of veterans with PTSD who reported distress related to killing in war or feeling responsible for the death of others. Primary exclusion criteria were a psychotic disorder diagnosis, moderate or severe alcohol or substance use disorder, untreated mania, or recent suicidal or homicidal behavior. Interventions IOK, an individual psychotherapy that focuses on killing cognitions, acceptance, self-forgiveness, and moral repair, and PCT, which addresses current functional issues due to moral distress with related problem-solving. Main Outcomes and Measures The primary outcomes were psychosocial functioning assessed by the World Health Organization Quality of Life Scale–Brief (WHOQOL-BREF) and the Sheehan Disability Scale (SDS). Secondary outcomes included PTSD and MI measures. Results A total of 100 individuals (98 male; mean [SD] age, 48.4 [13.7] years) were randomized. Linear mixed models revealed that psychosocial functioning improved for both groups at posttreatment (WHOQOL-BREF and SDS) and the IOK group had a significantly greater improvement than those in PCT on the SDS (−3.50; <jats:italic>z</jats:italic> score, −2.42; Cohen <jats:italic>d</jats:italic> , −0.51; <jats:italic>P</jats:italic> = .02; 95% CI, −5.65 to −0.59). There was no significant difference between treatments on the WHOQOL-BREF at posttreatment. Compared to PCT participants, IOK participants also reported significantly greater improvement in PTSD and MI symptoms. Conclusions and Relevance Individuals in both treatments improved on measures of psychosocial functioning (WHOQOL-BREF and SDS). Those who received IOK evidenced greater improvements in work or school, social life, and home or family life (as measured by the SDS) compared to those in PCT at posttreatment. IOK participants also reported improved PTSD and MI symptoms. The findings suggest that IOK may improve several outcomes for those who experience distress due to killing in war. Trial Registration ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http://www.w3.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"35 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148675368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Study Design for Clinically Useful Peripheral Molecular Biomarker Discovery in Psychiatry","authors":"Chloe X. Yap, Anjali K. Henders, Naomi R. Wray, Rachel Upthegrove","doi":"10.1001/jamapsychiatry.2026.2299","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2299","url":null,"abstract":"Importance Psychiatric diagnosis, prognosis, and management currently rely on subjective assessments. There is hope that peripheral (eg, blood) biomarkers or combinations thereof could transform clinical care by bringing objectivity and patient stratification while being accessible and scalable. The time is ripe to find molecular biomarkers: omics technologies can now profile hundreds to millions of molecules across thousands of individuals, while funders recognize the clinical need and have responded with ambition. However, this enthusiasm will likely be finite, and there is no guarantee that a biomarker will be found. Observations It is essential to design and perform studies that are most likely to deliver robust peripheral biomarkers with a clear path to translation. This narrative review provides recommendations to optimize peripheral psychiatric biomarker study design. The review first introduces conceptual grounding illustrating how biomarker study design must triangulate clinical utility, technological fit, and biological plausibility. Biomarker studies should optimize for signal-to-noise ratio via careful phenotype selection and minimization of biological and technical noise. However, feasibility issues—in collecting sufficient data on enough representative participants for an adequately powered and clinically translatable analysis—constrain study design. Conclusions and Relevance Study design is the single most influential and controllable factor for future psychiatric biomarker discovery. This is because many years elapse between study design and data analysis (particularly for biobanked samples held for future use) and because no technological or analytical advances can answer questions that the dataset was not designed for, or overcome unmeasured confounding. Moreover, the direction of biomarker research is constrained by what is possible to design. Many clinical questions and contexts need biomarkers, but realistically, some are better primed for biomarker discovery than others. In this generation of peripheral psychiatric biomarker studies, designs most likely to demonstrate proof-of-principle should be prioritized to ensure the long-term sustainability of the field.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"54 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148675279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blinding Integrity and Psychedelic Drug Trials-Reply.","authors":"Wieslaw J Cubala, Velichka Valcheva, Michael E Thase","doi":"10.1001/jamapsychiatry.2026.2296","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2296","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":18.0,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blinding Integrity and Psychedelic Drug Trials.","authors":"Tien-Wei Hsu, Chih-Sung Liang, Yu-Kang Tu","doi":"10.1001/jamapsychiatry.2026.2290","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2290","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":18.0,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Treatment Can Promote Recovery-Reply.","authors":"Nurul Husna Salahuddin, Stefan Leucht, Irene Bighelli","doi":"10.1001/jamapsychiatry.2026.1383","DOIUrl":"10.1001/jamapsychiatry.2026.1383","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"883"},"PeriodicalIF":18.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Confounding and Circularity in Actigraphy Prediction.","authors":"Yu Xiao","doi":"10.1001/jamapsychiatry.2026.1290","DOIUrl":"10.1001/jamapsychiatry.2026.1290","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"883-884"},"PeriodicalIF":18.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148030592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structure of the Genetic Risks for Psychiatric Disorders in Swedish Population-Based Registries.","authors":"Kenneth S Kendler, Henrik Ohlsson, Jan Sundquist, Kristina Sundquist","doi":"10.1001/jamapsychiatry.2026.1047","DOIUrl":"10.1001/jamapsychiatry.2026.1047","url":null,"abstract":"<p><strong>Importance: </strong>Recent efforts to clarify the structure of the genetic risks for psychiatric disorders have been limited to disorders with large molecular samples. These heterogeneous samples have typically been ascertained from diverse sources and use a widening range of diagnostic approaches including single-item self-reports.</p><p><strong>Objective: </strong>To assess the structure of genetic risk factors for 18 diverse psychiatric and substance use disorders in a single population, using high-quality population-based registries.</p><p><strong>Design, setting, and participants: </strong>This cohort study included individuals born between 1960 and 2000 in Sweden to Swedish-born parents who were followed up to a mean (SD) age of 40.9 (10.5) years in 2018. Registries included the Swedish Multigeneration Register and Swedish National Patient Register. Data were analyzed from September to December 2025.</p><p><strong>Exposures: </strong>The family genetic risk scores (FGRSs) for 18 disorders in all individuals calculated from first- through fifth-degree relatives, controlling for cohabitation.</p><p><strong>Main outcomes and measures: </strong>Exploratory and confirmatory factor analysis (EFA and CFA, respectively) of these FGRSs performed on split-half samples.</p><p><strong>Results: </strong>Among 3 021 948 individuals (1 549 159 [51.3%] male), EFA found a 6-factor structure consisting of psychotic disorders, externalizing disorders, anxiety disorders, neurodevelopmental disorders, mood disorders, and eating disorders. The mean (SD) interfactor correlation was 0.29. The CFA fit well and set 70.3% of the loadings to 0. Interesting features included identification of separate mood and anxiety disorder factors, with major depression loading on both; bipolar disorder, schizoaffective disorder, and acute psychoses all loading on the mood and psychotic disorder factors, with loadings on the mood disorder factor stronger for bipolar disorder than the psychotic disorder factor and the reverse seen for schizoaffective and acute psychotic disorder; posttraumatic stress disorder having the most diverse loadings on the mood, anxiety, and externalizing disorder factors; and attention-deficit/hyperactivity disorder loading on both the neurodevelopmental and externalizing factors. Because FGRSs are skewed, especially for rare disorders, a range of transformations was performed to reduce skewness, which produced results similar to those obtained on the original data.</p><p><strong>Conclusions and relevance: </strong>Using a complete epidemiological ascertainment frame for treated psychiatric disorders in a large population sample with high-quality registries, this cohort study uncovered a structure of genetic risks that, compared to prior efforts, was similar in many ways but also had important differences.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"818-826"},"PeriodicalIF":18.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain Morphology Mediators of the Association of Childhood Trauma With Bipolar Disorder: An International ENIGMA Bipolar Disorder Working Group Study.","authors":"Leonardo Tozzi, Maria R Dauvermann, Emma Corley, Andrea Fernandes, Melody J Y Kang, Yanghee Im, Leila Nabulsi, Roberto Goya-Maldonado, Klaus Berger, Marco Hermesdorf, Hilary P Blumberg, Lejla Colic, Tamsyn E Van Rheenen, Elysha Ringin, Susan L Rossell, James A Karantonis, Lisa S Furlong, Tilo Kircher, Frederike Stein, Udo Dannlowski, Dominik Grotegerd, Jair C Soares, Mon-Ju Wu, Giovana B Zunta-Soares, Benson Mwangi, Joaquim Radua, Enric Vilajosana, Eduard Vieta, Melissa J Green, Emilie Olie, Guillaume Clain, Francesco Benedetti, Elisa Melloni, Beatrice Bravi, Delfina Janiri, Daniela Vecchio, Fabrizio Piras, Nerisa Banaj, Gabriele Sani, Gloria Roberts, Janice M Fullerton, Bronwyn J Overs, Philip B Mitchell, Jonathan Savitz, Lakshmi N Yatham, Josselin Houenou, Marion Leboyer, Amanda Rodrigue, David C Glahn, Sophia I Thomopoulos, Neda Jahanshad, Paul M Thompson, Ole A Andreassen, Christopher R K Ching, Dara M Cannon, Yann Quidé","doi":"10.1001/jamapsychiatry.2026.1183","DOIUrl":"10.1001/jamapsychiatry.2026.1183","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Childhood trauma is associated with increased risk for bipolar disorder, but the biological mechanisms of this association remain incompletely defined. Gray matter differences observed after trauma exposure overlap with those reported in bipolar disorder, suggesting that the association of childhood trauma with bipolar disorder might be mediated through brain morphology.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To determine whether cortical thickness, cortical surface, or subcortical volume mediate the association of childhood trauma with bipolar disorder.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This case-control study conducted a cross-sectional analysis of individuals with bipolar disorder and healthy controls from 19 international cohorts (Enhancing NeuroImaging Genetics Through Meta-Analyses [ENIGMA] Bipolar Disorder Working Group) from January 2010 to December 2022. Data were analyzed from January 2025 to January 2026.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;The primary exposure was the severity of total childhood trauma assessed with the Childhood Trauma Questionnaire, with secondary analyses of 5 subscales (emotional neglect and abuse, physical neglect and abuse, and sexual abuse).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary outcome was bipolar disorder diagnosis (case vs control). The primary measure was the mediation effects of childhood trauma on diagnosis via gray matter (75 bilateral-averaged cortical thickness, surface, and subcortical volume measures). The mediation pathway from severity of childhood trauma to bipolar disorder through brain morphology was specified a priori. High-dimensional mediation analysis, with leave-one-site-out cross-validation and permutation testing for significance (false discovery rate [FDR]), was conducted.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The final sample included 2221 healthy controls (mean [SD] age, 35.6 [13.2] years; 1274 female [57%]) and 1031 participants with bipolar disorder (mean [SD] age, 38.6 [13.7] years; 579 female [56%]). Severity of childhood trauma was directly associated with higher likelihood of having a bipolar disorder diagnosis (median coefficient, 0.841; 95% CI, 0.834-0.851; range, 0.776-0.893; FDR P &lt; .001). Less than 1% of the association between childhood trauma and bipolar disorder was mediated by brain morphology. Statistically significant mediators were hippocampal volume (median coefficient, 0.004; 95% CI, 0.002-0.005; range, 0-0.008; FDR P &lt; .001), medial orbitofrontal gray matter thickness (median coefficient, 0.002; 95% CI, 0.002-0.003; range, 0-0.004; FDR P &lt; .001), and superior frontal gyrus gray matter thickness (median coefficient, 0.002; 95% CI, 0.002-0.003; range, 0-0.005; FDR P &lt; .001).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This study found that severity of childhood trauma exposure was associated with bipolar disorder diagnosis in part through a smaller hippocampus, thinner cortex in the medial orbi","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"847-856"},"PeriodicalIF":18.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13234754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial.","authors":"Éimear M Foley, Nicholas Turner, Ruta Margelyte, Hannah J Jones, Muzaffer Kaser, Glyn Lewis, Peter B Jones, Golam M Khandaker","doi":"10.1001/jamapsychiatry.2026.1053","DOIUrl":"10.1001/jamapsychiatry.2026.1053","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Interleukin 6 (IL-6), a keystone inflammatory cytokine, is a credible mechanistic candidate for causing depression. However, randomized clinical trials testing its treatment potential remain scarce.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To identify likely treatment-sensitive outcomes and effect size for systemic IL-6 inhibition in patients with difficult-to-treat depression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This 4-week, proof-of-concept, double-blind, parallel-arm, placebo-controlled randomized clinical trial recruited adults with moderate-to-severe International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) depression, poor antidepressant response, low-grade systemic inflammation (high-sensitivity C-reactive protein [hs-CRP] level ≥0.3 mg/dL on 2 tests), and depression somatic symptoms (Beck Depression Inventory II somatic symptoms score ≥7) from primary and secondary care and self-referral from 2018 to 2022. Participants were randomized into minimization balanced groups on depression severity and sex. Assessments were conducted at baseline and 7, 14, and 28 days after infusion. Data were analyzed from 2023 to 2025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention: &lt;/strong&gt;Single intravenous infusion of IL-6R antagonist tocilizumab (8 mg/kg, maximum 800 mg/patient) or normal saline.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary outcome was depression somatic symptoms at 14 days after infusion. The secondary outcome was total depression severity. Exploratory outcomes included fatigue, anxiety, anhedonia, quality of life, and cognition. Outcomes were assessed using validated scales and interpreted against clinically meaningful thresholds.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 30 participants (mean [SD] age, 41.1 [12.3] years; 24 [80.0%] female) were randomized, including 14 in the tocilizumab group and 16 in the placebo group. Of these, 29 participants received the assigned infusion and completed follow-up. As expected for a small proof-of-concept study, no results reached statistical significance, including little improvement in depression somatic symptoms at day 14 (adjusted mean difference: -0.12; 95% CI, -2.51 to 2.28). However, a pattern of greater stepwise improvement over time was observed with tocilizumab in somatic symptoms, depression severity, fatigue, psychological symptoms, state anxiety, and quality of life, with the largest effects observed at the final follow-up (day 28). Tocilizumab may also improve more individual depressive symptoms. Treatment effects were within ranges considered clinically meaningful for depression severity, fatigue, anxiety, and quality of life. At the final follow-up, remission (7 participants [53.9%] vs 5 participants [31.3%]; number needed to treat [NNT] = 5) and response (6 participants [46.2%] vs 3 participants [18.8%]; NNT = 4) rates favored tocilizumab compared with placebo. Baseline hs-CRP level, but no","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"857-863"},"PeriodicalIF":18.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}